2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
20
Prostatic Neoplasms
7
Triple Negative Breast Neoplasms
6
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Hematologic Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Recurrence
2
Neoplasms
2
Multiple Myeloma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Leukemia
2
Healthy Participants
2
Disease Progression
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumour
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Interventions
Rituximab
161
Cyclophosphamide
142
fludarabine phosphate
89
Peripheral Blood Stem Cell Transplantation
81
Filgrastim
59
Mycophenolic Acid
58
Whole-Body Irradiation
53
Cyclosporine
53
Radiotherapy
52
Lenalidomide
47
Busulfan
45
Tacrolimus
44
Etoposide
43
Antilymphocyte Serum
41
Melphalan
37
Methotrexate
31
fludarabine
30
Bortezomib
30
Prednisone
28
Bendamustine Hydrochloride
28
Cytarabine
24
Cord Blood Stem Cell Transplantation
23
obinutuzumab
22
Vincristine
22
Methylprednisolone
21
Flow Cytometry
21
ibrutinib
19
venetoclax
18
zanubrutinib
17
sargramostim
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell, Marginal Zone
×
capivasertib
×
Clear all
NCT05008055
2024-12-20
CAPITAL
AstraZeneca
Phase 2
Completed
30 enrolled
15 charts